Learn to trade in these market conditions - Click here Just Released!
Medarex Challenges Resistance On Increased Volume -
Medarex to Present at the RBC Capital Markets Healthcare Conference -
Medarex initiates Phase Ib cancer trial -
MEDX: Begins Phase 1 Trial MDX-1106 Antibody to Treat Cancer -
Medarex Inc announces milestone payment for completion of Phase 2 trial of CNTO 95 -
Medarex obtains milestone payment from Centocor R&D -
Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors -
Medarex reports positive top-line results from Phase II diarrhea trial -
MEDX: Phase 2 Trial of Antibody for C. difficile Diarrhea Meets Primary Endpoint -
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R) -
MEDX: To Present At UBS Global Life Sciences Conference @ 16:30 ET [delayed] -
Medarex (MEDX) NewsBite - Medarex Higher Despite Downgrade -
MEDAREX SLUMPS 3.5% AT $6.68; CUT TO NEUTRAL FROM OVERWEIGHT AT JPMORGAN -
Medarex receives milestone payment from Pfizer -
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology -
MEDX: To Present At Thomas Weisel Healthcare Conference @ 09:10 ET [delayed] -
Medarex to Present at the Thomas Weisel Partners Healthcare Conference -
Medarex (MEDX) NewsBite - One Of Today's Top Losers So Far -
FDA approves Medarex's IND application for cancer drug -
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
